English Archives - Lipum AB (publ) Press Releases

Lipum Announces Peer-Reviewed Publication of Positive First-in-Human Phase I Results for SOL-116

Lipum today announced that results from the First-in-Human (FIH) Phase I trial of its drug candidate SOL-116 have been published in the peer-reviewed journal RMD Open. SOL-116 is a first-in-class humanised monoclonal antibody targeting bile salt-stimulated lipase (BSSL), a novel mechanism for rheumatoid arthritis (RA) and other chronic inflammatory diseases. The randomised, double-blind, placebo-controlled trial [...]

2026-07-06T14:20:00+02:00

Lipum secures an EUR 8 million Horizon Europe grant

Lipum has signed the grant agreement for BEYOND, a project selected by Horizon Europe under the call “Boosting the translation of biotech research into innovative health therapies”. The project has been awarded a total grant of approximately EUR 8 million, of which Lipum’s share is approximately EUR 5.5 million. The funding will support the continued [...]

2026-07-02T10:35:00+02:00

The merger between Flerie and Lipum has been completed

THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD ALSO NOT BE DISTRIBUTED IN OR INTO ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION REQUIRES ANY OTHER DOCUMENTATION, REGISTRATION, OR MEASURES BEYOND WHAT IS GOVERNED BY SWEDISH [...]

2026-03-20T11:00:00+01:00

The Swedish Companies Registration Office has granted permission to implement the merger plan between Flerie and Lipum

THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD ALSO NOT BE DISTRIBUTED IN OR INTO ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION REQUIRES ANY OTHER DOCUMENTATION, REGISTRATION, OR MEASURES BEYOND WHAT IS GOVERNED BY SWEDISH [...]

2026-03-12T12:30:00+01:00

Lipum selected for Horizon Europe grant

Lipum announces that the company is leading a consortium that has been selected, pending final negotiations, for an EUR 8 million grant from the Horizon Europe Research and Innovation Programme, under the call “Boosting the translation of biotech research into innovative health therapies”. After reviewing the invitation to grant preparation, the consortium has confirmed that [...]

2026-03-10T08:14:00+01:00

Lipum AB – Year-end report 2025

Lipum AB (publ) has published the Q4 interim and year-end report for 2025. Below is a summary, a complete report (only in Swedish) is available on the company's website. Financial summary January – December 2025Other operating income: 1 929 KSEK (911)Result after financial items: -71 526 KSEK (-55 516)Cash and cash equivalents as of June 30: [...]

2026-02-25T08:00:00+01:00

Lipum AB – interim report Q3 for the period July-September 2025

Lipum AB (publ) has published the interim report Q3 for the period July-September 2025. Below is a summary, a complete report (only in Swedish) is available on the company's website. Financial summary July – September 2025Other operating income: 457 KSEK (109)Result after financial items: -14 027 KSEK (-1 680)Cash and cash equivalents as of June 30: [...]

2025-11-27T08:00:00+01:00

STATEMENT BY THE BOARD OF DIRECTORS OF LIPUM IN VIEW OF THE MERGER OFFER BY FLERIE

The Board of Directors of Lipum AB (publ) (“Lipum”) unanimously recommends the shareholders of Lipum to vote in favour of the completion of the merger between Lipum and Flerie AB (publ) (“Flerie”) announced by press release today 18 November 2025 (the “Merger”). The Board of Directors believes that the Merger will create better conditions for [...]

2025-11-18T08:43:16+01:00

Flerie and Lipum have agreed on a merger plan

THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD ALSO NOT BE DISTRIBUTED IN OR INTO ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION REQUIRES ANY OTHER DOCUMENTATION, REGISTRATION, OR MEASURES BEYOND WHAT IS GOVERNED BY SWEDISH [...]

2025-11-18T08:10:46+01:00

Lipum presents new topline data supporting BSSL’s role in rheumatoid arthritis

Lipum AB (publ) today announced topline results from collaborative studies with Senior Associate Professor Alf Kastbom and team at Linköping University that further support the role of bile salt-stimulated lipase (BSSL) in rheumatoid arthritis (RA). The data from 263 subjects show that patients with recent-onset RA (n=174) have significantly higher BSSL levels in the circulation [...]

2025-10-30T08:30:00+01:00